Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Aptose Biosciences ( (TSE:APS) ) has issued an announcement.
On May 20, 2025, Aptose Biosciences announced the dosing of the first patient with 120 mg of tuspetinib in their Phase 1/2 TUSCANY trial, following a favorable safety review by the Cohort Safety Review Committee. The trial aims to develop a safe and effective frontline therapy for diverse AML populations, and the escalation to 120 mg dosing was endorsed due to promising results from earlier cohorts.
The most recent analyst rating on (TSE:APS) stock is a Buy with a C$210.00 price target. To see the full list of analyst forecasts on Aptose Biosciences stock, see the TSE:APS Stock Forecast page.
Spark’s Take on TSE:APS Stock
According to Spark, TipRanks’ AI Analyst, TSE:APS is a Underperform.
Aptose Biosciences faces significant financial distress with no revenue generation and substantial losses. The negative technical indicators and valuation metrics further highlight the stock’s weak position. However, recent corporate events provide a glimmer of hope with potential advancements in AML treatment and strategic partnerships, slightly mitigating the overall risks. The stock remains risky, requiring cautious optimism for future developments.
To see Spark’s full report on TSE:APS stock, click here.
More about Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, with a particular emphasis on hematology. The company’s lead product, tuspetinib, is an oral kinase inhibitor being developed as a frontline triplet therapy for newly diagnosed acute myeloid leukemia (AML).
Average Trading Volume: 5,994
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$6.02M
For a thorough assessment of APS stock, go to TipRanks’ Stock Analysis page.